Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06532032 · ClinicalTrials.gov registry record · Phase 1

A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer

A Phase 1 study of Carcinoma, Non-Small Cell Lung, sponsored by Janssen Research & Development.

Active
Registry status
Phase 1
Development phase
12
Enrollment target
15
Study locations

NCT06532032 is a Phase 1 study of Carcinoma, Non-Small Cell Lung that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 12 participants, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (96% lower). The trial reports 15 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06532032, a Phase 1 study of Carcinoma, Non-Small Cell Lung, is active but no longer recruiting, sponsored by Janssen Research & Development.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
12 participants
Enrollment target
15
Study locations

Study Summary

The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and docetaxel combination therapy in participants with metastatic non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect of the combination at the selected RP2CD in participants with NSCLC without oncogenic driver mutations with disease progression on platinum-based chemotherapy and immune checkpoint inhibitor, in the Phase 2 (expansion).

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG Docetaxel
  • DRUG Amivantamab

Study Locations (15)

Other

  • Changhua Christian Hospital - Changhua
  • Kaohsiung Medical University Hospital - Kaohsiung City
  • Chi Mei Medical Center Liu Ying - Liou Ying Township
  • Taichung Veterans General Hospital - Taichung
  • National Taiwan University Hospital - Taipei
  • Taipei Medical University - Taipei
  • Ankara Bilkent Sehir Hastanesi - Çankaya
  • Leeds Teaching Hospitals NHS Trust - Leeds
  • The Royal Marsden NHS Trust - Sutton

California

  • UCI Health Irvine Hospital - Irvine
  • Cancer and Blood Specialty Clinic - Los Alamitos
  • University of California Irvine Medical Center Chao Family Comprehensive Cancer Center - Orange

Missouri

  • Oncology Hematology Associates - Springfield

New Jersey

  • Hunterdon Hematology Oncology - Flemington

Virginia

  • Virginia Cancer Specialists - Fairfax

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2024-07-23
Est. Completion 2026-06-09
Phase Phase 1

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06532032

The ClinicalTrials.gov registry entry for NCT06532032 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (96% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.

NCT06532032 reports 15 study locations spanning 5 distinct geographic areas - top geographies include Other, California, Missouri.

Frequently Asked Questions

What is clinical trial NCT06532032 about?

NCT06532032 is a clinical study titled "A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer". The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and docetaxel combination therapy in participants with metastatic non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect of the com...

What is the current status of trial NCT06532032?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-07-23. Estimated completion is 2026-06-09.

What conditions does trial NCT06532032 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT06532032?

The interventions under investigation include: Docetaxel (DRUG), Amivantamab (DRUG).

Who is sponsoring clinical trial NCT06532032?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06532032 being conducted?

This trial has 15 study locations across California, Missouri, New Jersey, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.